Baillie Gifford & CO Grifols Sa Transaction History

Baillie Gifford & CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Oct 19, 2021	SELL	$14.07 - $17.3 $41.5 Million - $51 Million	-2,948,016 Closed	0 $0
Q2 2021 Aug 02, 2021	SELL	$16.62 - $18.94 $5.05 Million - $5.76 Million	-304,132 Reduced 9.35%	2,948,016 $51.1 Million
Q1 2021 May 06, 2021	SELL	$15.15 - $19.78 $1.98 Million - $2.59 Million	-130,784 Reduced 3.87%	3,252,148 $56.2 Million
Q4 2020 Feb 10, 2021	BUY	$16.86 - $19.67 $1.51 Million - $1.76 Million	89,377 Added 2.71%	3,382,932 $62.4 Million
Q3 2020 Nov 12, 2020	SELL	$15.4 - $20.16 $31,847 - $41,690	-2,068 Reduced 0.06%	3,293,555 $57.1 Million
Q2 2020 Aug 12, 2020	BUY	$18.24 - $21.45 $2.19 Million - $2.57 Million	119,926 Added 3.78%	3,295,623 $60.1 Million
Q1 2020 May 08, 2020	BUY	$16.28 - $25.63 $51.7 Million - $81.4 Million	3,175,697 New	3,175,697 $64 Million

164

140M

288K

389K

Ticker GRFS
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 678,910,976
Market Cap $4.91B
Description
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solut...

Get notified when there are updates to the investment portfolio of Baillie Gifford & CO, based on Form 13F filings with the SEC.

Stay updated on Baillie Gifford & CO with notifications on news.